CPHA Canvax
CPHA Canvax

"Immunization is currently considered a cornerstone of public health practice in Canada. Fortunately, given the tremendous potential for immunization in terms of contributing to “public good”, currently available vaccines have a favourable safety record; most side effects are minor and serious complications are rare. Yet the continued success of immunization programs in Canada requires a comprehensive, effective and efficient vaccine safety system, including ongoing pre- and post-licensure testing and regulatory controls, as described in Paper 4, as well as vigilant post-market assessment of adverse events following immunization (AEFI), described herein. While manufacturers typically conduct Phase IV studies to evaluate vaccine safety and/or efficacy – and are also required by law to report serious AEFI – the majority of post-market vaccine safety reporting is conducted by health providers and public health authorities, as part of the extensive Public Health Agency of Canada (PHAC) surveillance framework". - Ensuring Vaccine Safety and Effectiveness for Canadians (Part 9 of Vaccine White Paper Series)


Web link

Ensuring Vaccine Safety and Effectiveness for Canadians

Related Resources

Bookmark

Background Knowledge

Link

Category

Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Monitoring and Surveillance,Vaccine Monitoring and Surveillance,Vaccine Monitoring Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Monitoring and Surveillance
Vaccine Monitoring and Surveillance
Vaccine Monitoring

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.